Cleveland Clinic may end use of J&J’s Natrecor

Share this article:
Heart doctors at the Cleveland Clinic have voted unanimously to curtail or even ban the clinic's use of Johnson & Johnson's Natrecor after two recent medical journal studies linked the heart failure treatment to an increase in kidney problems and death rates among patients.
A final decision is in the hands of a clinic committee expected to review data at a meeting today, a New York Times report said.
Opposition to Natrecor's use could be a serious blow to Johnson & Johnson. Last  December, the clinic took the lead in banning Pfizer's Bextra – months before the FDA asked for the drug to be withdrawn from the market because of heart risks.
J&J spokesman Mark Wolfe said in the Times report that his company would not speculate on the results of the clinic's committee review.
"From our perspective, Natrecor is highly effective and has a positive risk-benefit ratio when used in patients with acutely decompensated heart failure," he said.
While J&J's policy is not to release sales figures for Natrecor, analysts predicted sales of the drug could top $600 million this year and eventually reach blockbuster status.
J&J last week announced it agreed with the FDA to revise labeling for Natrecor to include data showing a slight increase of risk of death within 30 days for patients using the drug, compared with patients taking placebo or alternative treatments.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.